Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
A.R. Leff
European Respiratory Journal 2004 24: 334; DOI: 10.1183/09031936.04.00049604a
A.R. Leff
The University of Chicago, Chicago, IL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

From the authors:

We thank S. Hart for some important observations about our paper 1, and we concur that while we have postulated that the effect obtained with fluticasone could be related to apoptosis as one possible mechanism, we have not established the initiating mechanism of the interaction between β2‐adrenoceptor activation and flucticasone. In a prior publication, we used TUNEL assay 2, which showed no effect on apoptosis at 24 h for eosinophils incubated in an identical manner, as for the study in the current paper. Annexin‐I synthesis increased at 24 h and further increased at 48 h in that study. We have not tested annexin‐V or other potentially more sensitive means of detecting early apoptosis, as this was not the point of the paper. The hypothesis of the paper was that eosinophil adhesion, which is blocked partially (or not atall at low concentrations of fluticasone), would be blocked additively or synergistically by 30 min incubation with salmeterol. The addition of salmeterol for such a short period would not likely accelerate apoptosis in cells already exposed to fluticasone for 24 h. On the contrary, salmeterol has been shown to decrease apoptosis in eosinophils 3.

Rather than early apoptosis, our paper evaluated the ability of three different essential steps for eosinophils adhesion: 1) CD11b upregulation; 2) cPLA2 phosphorylation; and 3) cPLA2 translocation to the nuclear membrane. Neither of the first two processes was affected by fluticasone at 24 h, whereas the third process was blocked selectively. While it ispossible that early apoptosis could theoretically cause selective blockade of one of the three major processes regulating adhesion, we think that is unlikely, especially in view of the acute augmentation effect of salmeterol. Nonetheless, we acknowledge that this remains a possibility and we also concur with editorial of Papi 4, suggesting that more work on the upstream mechanism of the anti­adhesive effects demonstrated in our paper is in order.

Finally, we agree that trypan blue and propidium iodide, while used by other investigators to assess “viability” 5, do not exclude apoptosis, which is an effect of fluticasone 6. As noted above, we have verified previously that eosinophils treated in the presence of interleukin‐5 for 48 h demonstrated other indices of retained cellular function, including leukotriene synthetic function. We agree that the term viability is meaningless; likewise it is difficult to make assumptions about cell physiological functions based on histological assessment of early stages of apoptosis. In the event that early apoptosis is the mechanism selectively blocking this single, but critical, step in adhesion, we now know which physiological step is blocked. By assessing cell physiological functions, we now have some notion of where to look upstream to further define the mechanism.

  • © ERS Journals Ltd

References

  1. ↵
    Myo S, Zhu X, Meliton AY, et al. Additive blockade of β2‐integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J 2004;23:511–517.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Sano A, Munoz NM, Sano H, et al. Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med 1999;159:1903–1909.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000;106:77–83.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Papi A. Investigating the steroids and long­acting β2‐agonist combination: why do we need more? Eur Respir J 2004;23:501–502.
    OpenUrlFREE Full Text
  5. ↵
    Hagan JB, Kita H, Gleich GJ. Inhibition of interleukin‐5 mediated eosinophil viability by flucticasone 17‐propionate: comparison with other glucocorticoids. Clin Exp Allergy 1998;28:999–1006.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Zhang X, Moilan E, Kankaanranta H. Enchancement of human eosinophil apoptosis by fluticasone propionate, budesonide and becomethasone. Eur J Pharmacol 2000;406:325–332.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 24 Issue 2 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A.R. Leff
European Respiratory Journal Aug 2004, 24 (2) 334; DOI: 10.1183/09031936.04.00049604a

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A.R. Leff
European Respiratory Journal Aug 2004, 24 (2) 334; DOI: 10.1183/09031936.04.00049604a
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
  • Optimised surveillance of bronchial dysplasia in risky population
  • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society